Press "esc" to clear
Go to Advanced Search

Showing results

110 of 1048
  • Embargo expired:
    18-Jul-2018 2:00 PM EDT

Article ID: 697439

Study Finds Melanoma Biomarkers Predicting Checkpoint Blocker Response

Dana-Farber Cancer Institute

Scientists at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood of severe side effects.

Released:
17-Jul-2018 9:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 697607

Triple-Threat

University of Kansas Cancer Center

Triple-negative breast cancer expert Dr. Priyanka Sharma discusses latest research and clinical trial efforts.

Released:
18-Jul-2018 1:35 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Embargo will expire:
19-Jul-2018 11:00 AM EDT
Released to reporters:
18-Jul-2018 11:05 AM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 19-Jul-2018 11:00 AM EDT

Embargo will expire:
19-Jul-2018 2:00 PM EDT
Released to reporters:
18-Jul-2018 11:05 AM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 19-Jul-2018 2:00 PM EDT

HollyHarris.jpg

Article ID: 697542

Large study shows that early physical and sexual abuse is associated with a greater risk of endometriosis

Fred Hutchinson Cancer Research Center

A study of more than 60,000 women has found that sexual and physical abuse in childhood and adolescence is associated with a greater risk of laparoscopically-confirmed endometriosis diagnosed during adulthood. The study – the largest of its kind – found that women reporting severe-chronic abuse of multiple types had a 79 percent higher risk of laparoscopically-confirmed endometriosis.

Released:
17-Jul-2018 12:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
AfAmmanolder.jpg

Article ID: 697519

$26.5M Grant Helps Investigators ‘RESPOND’ to Prostate Cancer

Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey, the NJ State Cancer Registry and the NJ Department of Health are collaborating on a $26.5 million study examining African-American men and prostate cancer. The ‘RESPOND’ study is being led by the Keck School of Medicine at USC.

Released:
17-Jul-2018 11:55 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
BlueDesig_group.jpg

Article ID: 697382

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Recognized for Quality in Value Based Cancer Care

Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have been recognized with a Blue Distinction® Centers for Cancer Care designation as part of the Blue Distinction Specialty Care program.

Released:
12-Jul-2018 3:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
samir_hanash.jpg
  • Embargo expired:
    12-Jul-2018 11:00 AM EDT

Article ID: 697285

Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers

University of Texas M. D. Anderson Cancer Center

A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international research team reports in JAMA Oncology. “This simple blood test demonstrates the potential of biomarker-based risk assessment to improve eligibility criteria for lung cancer screening with low-dose computed tomography,” said study co-senior author Sam Hanash, M.D., Ph.D., professor of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center.

Released:
11-Jul-2018 11:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
main.jpg

Article ID: 697335

Deadly Form of Advanced Prostate Cancer Is Common, Calls for Distinct Treatment

UCSF Helen Diller Family Comprehensive Cancer Center

A new study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that a surprisingly large number of these cancers – about 17 percent – belong to a deadlier subtype of metastatic prostate cancer.

Released:
12-Jul-2018 10:55 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 697277

Ludwig Cancer Research and Cancer Research Institute Launch Clinical Trial Combining Virotherapy and Immunotherapy to Treat Advanced Colorectal and Ovarian Cancers

Ludwig Cancer Research

Ludwig Cancer Research and the Cancer Research Institute (CRI) announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI® (durvalumab) for advanced ovarian and colorectal cancers.

Released:
11-Jul-2018 12:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Showing results

110 of 1048





Chat now!